While in CM ARL11 was found upregulated, compared to normal skin tissue, in breast, lung, ovarian and prostate cancers, it was shown to be downregulated by DNA hypermethylation and genomic deletions [43,46]. This evidence concerns the gene ARL11 and prostate carcinoma.